Boothbay Fund Management LLC Has $2.76 Million Holdings in Boston Scientific Corporation $BSX

Key Points

• Boothbay Fund Management LLC boosted its stake in Boston Scientific by 1,079% in Q3 to 28,250 shares, valued at about $2.76 million.
• Multiple securities class actions and investor notices allege Boston Scientific misled investors about its U.S. Electrophysiology business, with law firms soliciting lead-plaintiff applicants ahead of the May 4, 2026 deadline, raising potential litigation and headline risk.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 for roughly $15.04 million, reducing his position by 10.23%, while insiders overall own about 0.50% of the stock.

Boothbay Fund Management LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 1,079.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,250 shares of the medical equipment provider's stock after acquiring an additional 25,854 shares during the quarter. Boothbay Fund Management LLC's holdings in Boston Scientific were worth $2,758,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $26,000. Steph & Co. bought a new stake in shares of Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after buying an additional 170 shares in the last quarter. Financial Consulate Inc. bought a new position in Boston Scientific during the 3rd quarter worth $25,000. Finally, United Community Bank increased its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 147 shares during the period. Institutional investors own 89.07% of the company's stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysis arguing the stock's pullback may be overdone given solid fundamentals and recent financial results, which helps explain why investors are buying despite legal headlines. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Negative Sentiment: Multiple securities class actions and investor notices allege Boston Scientific misled investors about growth and competitive risks in its U.S. Electrophysiology segment; law firms are soliciting lead-plaintiff applicants ahead of a May 4, 2026 deadline, increasing potential litigation exposure and headline risk. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Rosen Law Firm reminder: purchasers of BSX between July 23, 2025 and Feb 3, 2026 have until May 4, 2026 to seek lead-plaintiff status in the securities fraud action — more publicity and potential consolidation of claims. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Faruqi & Faruqi issues an investor reminder about the same May 4 deadline and is investigating potential claims tied to disclosures during the Class Period — another firm adding legal resources and publicity. BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors with substantial losses about opportunities to lead a class action, repeating allegations that the company misled investors on its U.S. EP segment — amplifies potential class consolidation and damages exposure. INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
• Negative Sentiment: Several other plaintiff firms (Glancy Prongay Wolke & Rotter; Bronstein Gewirtz & Grossman; additional Rosen/Faruqi notices) have filed or circulated similar investor-alerts — increasing the odds of coordinated litigation activity and legal costs for BSX. ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – BSX

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent analyst reports. UBS Group cut their target price on Boston Scientific from $140.00 to $120.00 and set a "buy" rating for the company in a research report on Thursday, February 5th. Argus upgraded Boston Scientific to a "strong-buy" rating in a research report on Thursday, February 26th. Truist Financial dropped their price target on Boston Scientific from $120.00 to $95.00 and set a "buy" rating for the company in a research note on Thursday, February 5th. Needham & Company LLC cut their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a "buy" rating for the company in a research report on Thursday, February 5th. Finally, Wells Fargo & Company reduced their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $108.00.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $69.77 on Tuesday. Boston Scientific Corporation has a one year low of $67.56 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a market cap of $103.53 billion, a price-to-earnings ratio of 35.96, a PEG ratio of 0.97 and a beta of 0.69. The firm has a 50 day simple moving average of $81.95 and a 200 day simple moving average of $92.95.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company's revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.